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Background: Diabetes mellitus type 1, formerly called insulin-dependent diabetes, is one of the autoimmune diseases where insulin-
producing cells are destroyed by autoimmune response via T cells. The new approaches in treatment of diabetes are using the stem cells, 
cell transplantation of islet β cell, gene transfer by virus based plasmids, and non-viral gene constructs.
Objectives: The purpose of this study was to construct glucose inducible insulin gene plasmid and use it in the muscle tissue of the rabbit.
Materials and Methods: To achieve this goal, the preproinsulin, metallothionein2A promoter and the response element to carbohydrate 
genes were cloned into pBIND plasmid by standard cloning methods, to construct pBINDMTChIns. The gene cloning products were 
confirmed by the polymerase chain reaction (PCR) and restriction enzyme digestion template. The recombinant plasmid, containing 
the preproinsulin gene, was transferred into NIH3T3 cells and insulin gene expression was evaluated by reverse transcriptase PCR and 
western blotting techniques. Plasmid naked DNA containing the preproinsulin gene was injected into the rabbits’ thigh muscles, and its 
expression was confirmed by western blotting method.
Results: This study shows the prepared gene construct is inducible by glucose. Gene expression of preproinsulin was observed in muscle 
tissue of rabbits.
Conclusions: These finding indicated that research in diabetes mellitus gene therapy could be performed on larger animals.
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1. Background
Type 1 diabetes (T1DM), is a polygenic disorder and au-
toimmune disease in which insulin-producing cells are 
destroyed by autoimmune response via T cells (1, 2), lead-
ing to many biochemical and clinical problems, including 
hyperglycemia, kidney failure, retinopathy, and neuropa-
thy (3). The classic treatment is using exogenous insulin, 
which is not sufficient to stable the blood glucose at nor-
mal level and could cause clinical complications (4, 5). 
Various procedures (such as pancreas transplantation, 
using stem cells, or islet cells) have been conducted to in-
duce better results with fewer side effects. However, these 
methods can cause serious problems like risks related to 
surgery, lack of pancreas, graft rejection of the pancreas, 
and high cost (6, 7).
 The other strategy is immunotherapy for suppress-
ing the immune system (8-10). In recent years, viral and 
non-viral gene constructs such as the retro-associated, or 
adeno-associated viruses, have been used for T1DM gene 
therapy as some novel approaches (11). Although, non-vi-
ral vectors are weak, they are safer than viral vectors, and 
researchers tend to use these plasmids (12, 13). Despite the 
great efforts in engineering the insulin production, the 
perfect system has not been established for the optimal 
control of glucose. In this study, insulin plasmid gene 
construct was prepared for T1DM gene therapy. As the 
insulin production depends on exact regulation of glu-
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cose levels, the plasmids were constructed for the same 
purpose. Vectors containing glucose 6-phosphatase and 
GLUT-2 promoter have already been used in cell lines and 
animal tissues of mice and rat (14, 15).
2. Objectives
Considering that diabetes mellitus is increasing in 
the world, and the classical treatment cannot improve 
disease appropriately; therefore, we designed pBIND eu-
karyotic vector consisting of the metallothionein2A pro-
moter, the carbohydrates response element, and human 
preproinsulin gene (Gen Bank: JQ951950.1). We tested its 
responsiveness to glucose in rabbit.
3. Materials and Methods
3.1. Total RNA Extraction From Human Pancreatic 
Tissue and RT-PCR Reactions
Normal pancreas (from patients with brain death) was 
obtained from the Organ Bank of Imam Khomeini Hos-
pital, Tehran, and immediately frozen in liquid nitrogen 
and saved at -80°C. Pancreatic tissue total RNA was ex-
tracted using the RNA extraction kit (QIAGEN) according 
to the manufacturer's protocol. Total RNA concentration 
was determined by Eppendorf Biophotometer and RNA 
integrity was confirmed by electrophoresis technique on 
1.2% agarose gel (16). Synthesis of cDNA was performed 
by reverse transcription reaction using the 1 µg RNA, 2 
µL random hexamer RT-Primer, 1x RT buffer, 50 U Multi-
ScribeTMRT enzyme (Invitrogen™), 4.2 µL nuclease free 
water, 0.2 mM dNTP in 20 µL final volume. Then, the 
given master mix was incubated at 25˚C for 10 minutes 
and then at 37˚C for 120 minutes. The polymerase chain 
reaction was performed for gene amplification using the 
human preproinsulin forward and reverse primers (The 
primers prepared from MWG Company, Germany). The 
forward primer sequence was 5`-GCGGCCGCATGGCCCT-
GTGGATGCGC-3` and the reverse primer sequence was 
5`-GGTACCCTAGTTGCAGTAGTTCTCCAG-3`. The primers 
contained NotI and KpnI restriction sites on the 5`ends. 
The forward and reverse universal primers for pBlue-
ScriptSK (+) plasmid were 5`-GTAAAACGACGGCCAGT-3` 
and 5`- CAGGAAACAGCTATGAC-3`, respectively.
3.2. Cloning the Preproinsulin Gene
The pMNTCh plasmid containing metallothionein2A 
(MT2A) promoter and carbohydrate response element 
(ChoRE) was gifted by Prof. O L Kan. BamHI and NotI 
restriction enzymes (Takara Bio, Japan) were used for 
isolating MT2A promoter and ChoRE sequences. The pu-
rification of the given DNA sequences was performed by 
gel extraction kit (QIAGEN), ligated to BamHI and NotI 
digested pBIND plasmid, and named pBINDMTCh. PCR 
method was used to amplify the preproinsulin gene se-
quence. The PCR product was ligated to pBlueScriptSK 
(+) cloning vector by T/A cloning method and then was 
transformed into B21 E. coli strain as a competent cell.
For plasmid extraction, colonies were cultured, then 
extracted plasmids were electrophoresed on 1% agarose 
gel (17). The plasmid containing preproinsulin gene 
was digested by NotI and KpnI restriction enzymes and 
inserted into the pBINDMTCh and produced pBIND-
MTChIns plasmid.
3.3. Cell Culture and Transfection
NIH3T3 cell line was obtained from National Cell bank 
of Iran (NCBI) (C156). The cells were incubated in DMEM 
media (Dulbecco's Modified Eagle's Medium, Sigma-
Aldrich Co.), containing 2 mM glutamine, 10% fetal calf 
serum (FCS) and penicillin-streptomycin (100 U/mL and 
0.1 mg/mL, respectively) at 37˚C and 5% CO2 in humidi-
fied air incubator (18). Four groups of NIH3T3 cells were 
used. The cells in the first group were negative control 
that received no substance. The second group was also 
negative control that received preproinsulin gene free 
plasmid. The third group was treated by pBINDMTChIns, 
and the fourth group by pBINDMTChIns plasmid and 16 
mmol/L glucose. Three hours before transfection, cells 
were incubated with fresh medium. While NIH3T3 cells 
covered 50%-80% of the cultured surface, transfection 
was performed. Nearly 4 × 105 cells per 35 mm-plate were 
used for transfection. Transfection solution containing 
5 µg of plasmid was incubated at 25˚C for 20 minutes 
and then added slowly as droplets to the plate. Plates 
were incubated at 37˚C for 8 hours in a CO2 incubator. 
Then the medium containing calcium-phosphate was 
removed and the cells were washed with culture medi-
um. Plates were fed with 2 mL of complete growth me-
dium and 16 mmol/L glucose and were incubated at 37˚C 
for 24 hours until gene expression analysis were carried 
out. Total RNA was extracted by the Fermentas total RNA 
purification kit and gene expression was examined by 
RT-PCR and also protein expression was examined by 
western blotting method using anti-human insulin 
antibodies. At first, proteins were electrophoresed by 
SDS-PAGE method, and then the bands were transported 
to a nitrocellulose paper sheet. Uncovered surfaces of 
the paper sheets were blocked by milk proteins. Subse-
quently, the paper sheets were incubated with an anti-
body against insulin and secondary antibody that was 
conjugated with horse-radish peroxidase (HRP). Finally, 
the substrate was added to nitrocellulose to visualize 
the detected bands.
3.4. Animal Studies
3.4.1. Preparing Diabetic Animals
Male New Zealand white rabbits weighing 1300 ± 200 
g were purchased from Pasteur Institute of Iran (IPI). 
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Animals were kept on standard chow with free access to 
food and water and in controlled conditions (19, 20). For 
environmental adaptation, rabbits were kept under the 
condition mentioned above for one week. Animals were 
divided into four groups containing five rabbits in each. 
The first group of rabbits (control, normal non-diabetic) 
were injected by 1 mL of sterile citrate buffer (pH = 4.5). 
Diabetes was induced in the second (diabetic control), 
third, and fourth groups using alloxan injection. Alloxan 
was dissolved in fresh sterile citrate buffer (pH = 4.5) and 
then the solution (175 mg/kg) was administered intrave-
nously after overnight fasting. Diabetic animals were ver-
ified as weight loss and fasting blood glucose concentra-
tions greater than 300 mg/dL at three days after alloxan 
injection (20). Glucometer (BioNime GM300) was used 
to measure blood sugar (glucose oxidase method). Blood 
sampling was performed in animals marginal ear vein 
before and after treatment with alloxan.
3.5. Intramuscular Injection of Plasmid
The second group of diabetic rabbits was injected with 
empty pBIND plasmid. The third group (as the control 
group) was injected by 2 mL of endotoxin-free PBS into 
the thigh muscle and the fourth group was injected with 
pBINDMTChIns plasmid. Before injection, pBINDMTChIns 
plasmid was tested by LAL (Limulus Amebocyte Lysate) 
pyrogen test (21). Four milliliter of plasmid solution con-
taining 400 µg of the plasmid DNA was injected into rab-
bits’ thigh muscles. Four days later, blood samples were 
taken from the marginal ear vein of all rabbits. Then all 
animals were killed by a large dose of pentobarbital (100 
mg/kg IV) and their muscles were collected and immedi-
ately frozen in liquid nitrogen (19). Total RNA was extract-
ed from the tissues, and preproinsulin gene expression 
was investigated by RT-PCR and western blotting using 
specific antibodies.
4. Results
After mRNA extraction and reverse transcription of to-
tal mRNA to cDNA, agarose gel electrophoresis was used 
for detecting the PCR product bands as shown in Figure 1, 
where lane 2 shows the amplified proinsulin gene com-
pared with the low-range DNA ladder. Since proinsulin-
gene sequence contains 330 bp, the detected band in this 
region (Figure 1) confirmed the correct PCR reaction and 
products.
 Figure 2 shows the results of electrophoresis of digest-
ed and undigested pBINDMTCh plasmid on 1% agarose 
gel. In Figure 2, lane 1 shows that pBINDMTCh plasmid 
has been digested by BamHI and NotI restriction en-
zymes, thus both ChoRE gene and MT2A promoter were 
amplified together to show a band at the 3000 bp. Lane 
2 shows the linear pBIND plasmid that has been digested 
and become linear by NotI enzyme that is 6360 bp in 
length. Lane 3 shows the undigested pBINDMTCh plas-
mid, that it is 7817 bp in length.
Figure 1. Electrophoresis Pattern of PCR Product of Amplified Proinsulin 
Gene in Agarose Gel (2%)
Lane 1, DNA ladder marker; Lane 2, the 330 bp PCR product of preproin-
sulin gene.
Figure 2. Electrophoresis Pattern of Digested and Undigested pBIND-
MTCh Plasmid in 1% Agarose Gel
Lane 1, The BamHI and NotI digested pBINDMTCh; Lane 2, The linear pBIND 
plasmid that has been digested by NotI enzyme; Lane 3, The undigested 
pBINDMTCh; Lane 4, DNA ladder (high range).
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Figure 3. Electrophoresis of PCR Products of pBlueScriptSK(+) Plasmid 
Containing the Preproinsulin Gene on 2% Agarose Gel
Lane 1, The PCR product of pBlueScriptSK (+) plasmid using the plasmid 
universal primers; Lane 2, The DNA ladder; Lane 3, The PCR product of 
pBlueScriptSK(+) plasmid using the special preproinsulin gene primers.
Figure 4. Protein Analysis by Western Blotting on NIH3T3 Cell Culture 
Expressed Preproinsulin by Anti-human Insulin Antibody
Lane 1, Negative control (only NIH3T3 cell culture); Lane 2, NIH3T3 cells 
contained pBINDMTChIns and 300 mM glucose; Lane 3, NIH3T3 cell trans-
fected by pBINDMTChIns plasmid; Lane 4, Negative control (NIH3T3 cell 
was transfected by intact pBIND plasmid).
Figure 5. Western Blotting Analysis on Rabbit Thigh Muscle Expressed 
Proinsulin by Anti-human Insulin Antibody
Lane 1, Positive control (human insulin protein); Lane 2, extraction of rab-
bit thigh muscle transfected by pBINDMTChIns plasmid.
 Figure 3 shows the results of electrophoresis of PCR 
products of pBlueScriptSK (+) plasmid containing the 
preproinsulin gene on 2% agarose gel. Lane 1, shows the 
PCR product of pBlueScriptSK (+) plasmid using the plas-
mid universal primers, that it is 620 bp in length. Lane 
3, shows the PCR product of pBlueScriptSK (+) plasmid 
using the special preproinsulin gene primers, that its 
length is 330 bp. Thus, these results confirmed that the 
preproinsulin gene cloning has been performed cor-
rectly. Also, the DNA sequencing was performed (MWG 
Company, Germany) to confirm the presence of prepro-
insulin gene, and the gene sequence was registered in the 
Gene Bank (JQ951950.1) and published in world wide web 
(http://www.ncbi.nlm.nih.gov/genbank/).
 Figure 4 shows the protein analysis by western blotting 
on NIH3T3 cell culture expressed preproinsulin by anti-hu-
man insulin antibody. Lane 1, shows negative control, NI-
H3T3 cell line without receiving any plasmid, thus there is 
no band in this region. Lane 2, shows the NIH3T3 cells con-
taining pBINDMTChIns and 300 mM glucose, thus there is 
a relatively wide band in this region. Lane 3 shows NIH3T3 
cell transfected by pBINDMTChIns plasmid. The bands in 
this region, confirms correct transfection and protein pro-
duction. Finally, lane 4 shows the negative control, NIH3T3 
cell transfected by intact pBIND plasmid. Also, there is no 
band in this region like the lane 1.
4.1. Results of Diabetic Animals
The average amount of non-diabetic animals’ blood 
sugar was about 88 mg/dL. Average blood sugar level of 
diabetic animals in the groups 2, 3, and 4 were 345, 337, 
359 mg/dL, respectively. Free preproinsulin gene pBIND 
plasmid was injected to the second group of animals; 
endotoxin-free sterile PBS was injected to the third group 
and pBINDMTChIns plasmid was injected to the fourth 
group. The blood sugar levels after injection were 350, 
345 and 340 mg/dL respectively. Four days after injection, 
blood sampling was done, then the animals were sacri-
ficed. RNA was extracted from muscle tissue at the injec-
tion site, and the insulin gene expression was confirmed 
by RT-PCR and western blotting (Figure 5). In Figure 5, 
the band in lane 1 is related to positive control (human 
insulin protein as control) and the band in lane 2 is asso-
ciated with extraction of rabbit thigh muscle transfected 
by pBINDMTChIns plasmid, thus it confirms the protein 
expression.
5. Discussion
Diabetes mellitus type 1 is one of the metabolic dis-
eases caused by autoimmune destruction of islet β cells 
(22). Although, some developments have been made in 
improving pathologies of diabetes and the quality of 
patients’ life, no treatment has been effective in reduc-
ing clinical complications or reversing progression of 
the disease (23). Until now, many studies have been car-
ried out about type 1 diabetes gene therapy, but none of 
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them have been done on larger animals like rabbits. In 
this study, non-viral vector was made differently from 
other vectors and used in NIH3T3 cell line and rabbit 
muscle tissues, which its protein expression was shown 
for the first time. Here we also assessed whether produc-
tion of insulin in NIH3T3 cell line and rabbit muscle cell 
can be stimulated by glucose. So far, various therapeutic 
strategies have been used for improving type 1 diabetes, 
including functional pancreatic tissue or β cells trans-
plantation in type 1 diabetes patients and conversion of 
mesenchymal stem cells into pancreatic islet cells (24). 
Islet β cells transplantation as a promising therapy for 
type 1 diabetes patients can control blood glucose level 
and accomplish insulin; however, insulin therapy is 
still a major approach, because the pancreas donors are 
limited, and long-term immune system suppression is 
needed too (22, 25, 26). Nevertheless, there are many ma-
jor problems about islet transplantation such as adverse 
immune responses induced by the islet transplantation 
process, host autoimmunity recurrence, allorejection 
and shortage of organ donors (27).
 Therefore, researchers have been encouraged to use 
other approaches like unlimited expression vectors. Glu-
cose responsive insulin production is a principle regula-
tory component. Many attempts have been carried out 
for constructing insulin gene vector to response to glu-
cose that was led to use the promoters containing the 
glucose-responsive elements. This is not perfect; however, 
it looks to be efficient (28). Many efforts have been made 
to prevent graft rejection such as constructing retroviral 
vector and double-stranded adeno-associated virus sero-
type 8 (dsAAV8) containing IL-4 gene in combination with 
β cell growth factors by Gaddy and Kapturczak (23, 29). 
The Kapturczak`s designed vector had a desirable rate of 
protein expression, but there were some restrictions in 
carrying out and biosafety due to vector expression rates 
(29). On the other hand, Gaddy claimed that aDsAAV8 vec-
tors containing IL-4 gene along with hepatocyte growth 
factor/NK1 or GLP-1 under the control of the insulin pro-
moter would increase islet β cell proliferation rate and 
survival, in NOD mice, and reversed diabetes progression 
in approximately 10% of these mice (23).
 But one of the important differences of the mentioned 
vectors compared to our designed vector is that their 
structures were viral, thus their safety is disputed in the 
animal body. In comparison with designed non-viral vec-
tor expressing preproinsulin in this study, which can com-
pensate the weakness in insulin production; designed 
viral vectors by Gaddy and other researchers targeted the 
immune response to improve T1DM disease, although 
many clinical trials have been performed using antigen-
specific techniques and immune correcting drugs, they 
often have demonstrated too toxic or have been unable to 
prepare long-time islet β cell protection (30).
 For this reason, multiple therapeutic approaches 
should be used for the generation of new islet β cells. 
Typically, two types of non-viral and viral constructs have 
been designed to target cells for type 1 diabetes treat-
ment. Some researchers like Zipris designed retroviral 
vector of IL-4 gene for the correction of autoimmune 
T1DM (31), though there were still former problems as 
mentioned above about Gaddy and Kapturczak reports 
(23, 29). Using the recombinant viral vectors has been 
created numerous problems such as frequent adminis-
tration, unstable and variable expression, induction of 
immune response and hepatic inflammation, in spite of 
positive performance and high transfer efficiency (32), 
while in this study, we tried to provide a new efficacious 
non-viral construct and consider the mentioned disad-
vantages about viral vectors immune response. Dong 
and colleagues used recombinant adeno-viral construct 
against experimental induced T1DM, and their results in-
dicated that the viral vectors have immunogenic effects 
and increase the inflammatory factors in CD-1 mice tis-
sues such as hepatic tissue (33). In addition, a remark-
able and contradictory result was also achieved in their 
report. They expected that insulin synthesis in liver in-
creases the glycogen, but the results indicated that in-
sulin production inhibited the glycogenesis in liver. It 
may be relevant to the cytokines. The same findings were 
also obtained by the hepatic insulin gene therapy (HIGT) 
demonstrating prevention of glycogen biosynthesis in 
hepatic cell culture medium by high concentrations of 
insulin and glucose (34).
Regarding so many drawbacks in the application of vi-
ral vector and use of hepatic tissues as target recipient 
tissue for gene delivery, we were encouraged to make 
non-viral vectors. However, we had previously developed 
a gene construct containing the insulin gene and MT2A 
promoter based on pcDNA3.1(-), but it lacked the GFP for 
gene expression detection (35). The designed vector in 
this study was made based on pBIND eukaryotic plasmid 
and contains bifunctional metallothionein2A promoter 
(MT2A) along with the carbohydrates response element 
(ChoRE) as multimer; basic metallothionein is expressed 
in the liver as metal cis-acting response element. The 
ChoREcis-acting element involved in glucose induced 
transcription, which contains two E-box and CACGTG 
motifs separated by 5 bp. The metallothionein2A is the 
main promoter sequence and helps glucose-induced 
transcription. On the other hand, due to capability of 
glucose responsive multimeric ChoRE, it was used as an 
auxiliary DNA element. The pBINDMTChIns is the first 
gene construct based on pBIND eukaryotic expression 
vector. It contained luciferase gene for easy detection 
of recombinant plasmid containing the insulin gene 
in cells and tissues as an advantage to other non-viral 
vectors. Testing pBINDMTChIns into NIH3T3 cell culture 
in the presence and absence of glucose as a stimulus 
showed the capability of inducing insulin production. 
The semi-quantitative proinsulin gene expression was 
detected by western blotting with satisfactory results, 
although for more accuracy, more advanced techniques 
such as Real-Time PCR are needed.
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 This study revealed that pBINDMTChIns can produce 
the preproinsulin in the NIH3T3 cell line so the glucose 
can act as a stimulant in this process. MT2A promoter in 
pBINDMTChIns vector has low ability to react to glucose 
stimulation, thus, adding ChoRE to MT2A promoter could 
enhance its ability. Concerning the existence of ChoRE as 
multiple copies following MT2A, this promoter can be 
an appropriate candidate for viral and non-viral vectors 
and even it can be used in liver tissues compared to L-
pyruvate kinase, glucose transporter-2 (GLUT-2), glucose 
6-phosphatase (14, 15), and glucagon-like peptide-1 (GLP-
1) promoters (36). However, using GLP-1 as a cell therapy-
based treatment may regulate blood sugar properly (28), 
but it may have immunogenic property that has not 
been known yet. Administration of naked recombinant 
plasmid into NIH3T3 cell indicates that the transfection 
has been carried out properly, and the non-viral gene con-
struct can be expressed and stimulated by glucose.
 These results could provide some information for sub-
sequent success in the progress of the non-viral gene 
constructs as new gene therapy approach. Since first ob-
servational studies have been accomplished by all kinds 
of vectors on various cell lines, the assessment of vectors 
is a substantial subject for passing from cell lines to ani-
mal models (33). Most viral and non-viral constructs were 
tested on small animals such as mice and rats, although 
the evolution of gene constructs are very important. On 
the other hand, it should be noted that achieving the 
ultimate goal of gene therapy for use in human eventu-
ally leads to the transition from small animals to larger 
animals. Therefore, in this study the rabbit was used as 
a host for non-viral construct for the first time, because 
of the similarity of its sugar metabolism to that of hu-
man (37). Also, there are a large number of similarities in 
terms of metabolism between humans and rabbits (20, 
38). Niessen performed a similar study on canine muscle 
cell line, whose results showed that muscle cell line could 
be induced to secrete canine insulin when transfected 
with non-viral vector containing a mutant canine prep-
roinsulin gene, which is able to produce furin enzyme 
cleavable preproinsulin in host cells (39).
Thus, observing the preproinsulin gene expression in 
pBINDMTChIns plasmid in NIH3T3 cell line and rabbit 
muscle tissue for the first time may be the basis for the 
subsequent investigations related to T1DM gene therapy 
on the large animals. Therefore, we recommend subse-
quent investigations study non-viral constructs on larger 
animal models and also the use of quantitative Real-Time 
PCR for evaluation of gene expression in cell lines and 
animal tissues.
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